Neoself Antigens Presented on MHC Class II Molecules in Autoimmune Diseases.

Autoantibody Autoimmune disease HLA MHC Misfolded protein

Journal

Advances in experimental medicine and biology

ISSN: 0065-2598

Titre abrégé: Adv Exp Med Biol

Pays: United States

ID NLM: 0121103

Informations de publication

Date de publication:
2024

Historique:

medline: 12 3 2024

pubmed: 12 3 2024

entrez: 12 3 2024

Statut: ppublish

Résumé

Major histocompatibility complex (MHC) class II molecules play a crucial role in immunity by presenting peptide antigens to helper T cells. Immune cells are generally tolerant to self-antigens. However, when self-tolerance is broken, immune cells attack normal tissues or cells, leading to the development of autoimmune diseases. Genome-wide association studies have shown that MHC class II is the gene most strongly associated with the risk of most autoimmune diseases. When misfolded self-antigens, called neoself antigens, are associated with MHC class II molecules in the endoplasmic reticulum, they are transported by the MHC class II molecules to the cell surface without being processed into peptides. Moreover, neoself antigens that are complexed with MHC class II molecules of autoimmune disease risk alleles exhibit distinct antigenicities compared to normal self-antigens, making them the primary targets of autoantibodies in various autoimmune diseases. Elucidation of the immunological functions of neoself antigens presented on MHC class II molecules is crucial for understanding the mechanism of autoimmune diseases.

Identifiants

DOI: 10.1007/978-981-99-9781-7_4 PMID: 38467972

pubmed: 38467972

doi: 10.1007/978-981-99-9781-7_4

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

51-65

Informations de copyright

Références

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582–7.

pubmed: 29217585 doi: 10.1126/science.aao4572

Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17(R2):R116–R21.

pubmed: 18852199 pmcid: 2782355 doi: 10.1093/hmg/ddn246

Caliskan M, Brown CD, Maranville JC. A catalog of GWAS fine-mapping efforts in autoimmune disease. Am J Hum Genet. 2021;108(4):549–63.

pubmed: 33798443 pmcid: 8059376 doi: 10.1016/j.ajhg.2021.03.009

Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee H-S, Jia X, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291–6.

pubmed: 22286218 pmcid: 3288335 doi: 10.1038/ng.1076

Onuma H, Ota M, Sugenoya A, Inoko H. Association of HLA-DPB1*0501 with early-onset graves’ disease in Japanese. Hum Immunol. 1994;39(3):195–201.

pubmed: 8026987 doi: 10.1016/0198-8859(94)90260-7

Takahashi M, Yasunami M, Kubota S, Tamai H, Kimura A. HLA-DPB1*0202 is associated with a predictor of good prognosis of graves’ disease in the Japanese. Hum Immunol. 2006;67(1–2):47–52.

pubmed: 16698425 doi: 10.1016/j.humimm.2006.02.023

Ueda S, Oryoji D, Yamamoto K, Noh JY, Okamura K, Noda M, et al. Identification of independent susceptible and protective HLA alleles in Japanese autoimmune thyroid disease and their epistasis. J Clin Endocrinol Metabol. 2014;99(2):E379–E83.

doi: 10.1210/jc.2013-2841

Okada Y, Momozawa Y, Ashikawa K, Kanai M, Matsuda K, Kamatani Y, et al. Construction of a population-specific HLA imputation reference panel and its application to Graves’ disease risk in Japanese. Nat Genet. 2015;47(7):798–802.

pubmed: 26029868 doi: 10.1038/ng.3310

Chen Q-Y, Huang W, She J-X, Baxter F, Volpe R, Maclaren NK. HLA-DRB1108, DRB1103/DRB310101, and DRB310202 are susceptibility genes for graves’ disease in north American Caucasians, whereas DRB1107 is Protective1. J Clin Endocrinol Metabol. 1999;84(9):3182–6.

Zamani M, Spaepen M, Bex M, Bouillon R, Cassiman J-J. Primary role of the HLA class II DRB1*0301 allele in graves disease. Am J Med Genet. 2000;95(5):432–7.

pubmed: 11146462 doi: 10.1002/1096-8628(20001218)95:5<432::AID-AJMG5>3.0.CO;2-7

Mignot E, Lin L. Narcolepsy. Encyclopedia Neurosci. 2009:7–14.

Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42(9):781–5.

pubmed: 20711177 pmcid: 2930111 doi: 10.1038/ng.642

Rapoport B, McLachlan SM. The thyrotropin receptor in Graves’ disease. Thyroid. 2007;17(10):911–22.

pubmed: 17822379 doi: 10.1089/thy.2007.0170

Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646–55.

pubmed: 12826640 doi: 10.1056/NEJMra021194

Jiang Y, Arase N, Kohyama M, Hirayasu K, Suenaga T, Jin H, et al. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int Immunol. 2013;25(4):235–46.

pubmed: 23334921 pmcid: 3597850 doi: 10.1093/intimm/dxs155

Jin H, Arase N, Hirayasu K, Kohyama M, Suenaga T, Saito F, et al. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. Proc Natl Acad Sci U S A. 2014;111(10):3787–92.

pubmed: 24567378 pmcid: 3956152 doi: 10.1073/pnas.1401105111

Tanimura K, Jin H, Suenaga T, Morikami S, Arase N, Kishida K, et al. β2-glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood. 2015;125(18):2835–44.

pubmed: 25733579 pmcid: 4424631 doi: 10.1182/blood-2014-08-593624

Tanimura K, Saito S, Nakatsuka M, Nagamatsu T, Fujii T, Fukui A, et al. The β 2 -glycoprotein I/HLA-DR complex as a major autoantibody target in obstetric antiphospholipid syndrome. Arthritis Rheumatol. 2020;72(11):1882–91.

pubmed: 32583563 doi: 10.1002/art.41410

Hiwa R, Ohmura K, Arase N, Jin H, Hirayasu K, Kohyama M, et al. Myeloperoxidase/HLA class II complexes recognized by autoantibodies in microscopic polyangiitis. Arthritis Rheumatol. 2017;69(10):2069–80.

pubmed: 28575531 doi: 10.1002/art.40170

Arase N, Tsuji H, Takamatsu H, Jin H, Konaka H, Hamaguchi Y, et al. Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. J Autoimmun. 2022;126:102774.

pubmed: 34896887 doi: 10.1016/j.jaut.2021.102774

Jin H, Kishida K, Arase N, Matsuoka S, Nakai W, Kohyama M, et al. Abrogation of self-tolerance by misfolded self-antigens complexed with MHC class II molecules. Sci Adv. 2022;8(9):eabj9867.

pubmed: 35245125 pmcid: 8896794 doi: 10.1126/sciadv.abj9867

Umino K, Morita K, Ikeda T, Kawaguchi S-i, Nagayama T, Ito S, et al. Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect. Blood. 2023;142(11):1008–21.

pubmed: 37363859 doi: 10.1182/blood.2023019799

Tsuji H, Ohmura K, Jin H, Naito R, Arase N, Kohyama M, et al. Anti-double-stranded DNA antibodies recognize DNA presented on HLA class II molecules of systemic lupus erythematosus risk alleles. Arthritis Rheumatol. 2022;74(1):105–11.

pubmed: 34164946 doi: 10.1002/art.41897

Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol. 1994;12:259–93.

pubmed: 8011283 doi: 10.1146/annurev.iy.12.040194.001355

Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 1992;358(6389):764–8.

pubmed: 1380674 doi: 10.1038/358764a0

Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature. 1995;378(6556):457–62.

pubmed: 7477400 doi: 10.1038/378457a0

Busch R, Cloutier I, Sékaly RP, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J. 1996;15(2):418–28.

pubmed: 8617217 pmcid: 449957 doi: 10.1002/j.1460-2075.1996.tb00372.x

Sercarz EE, Maverakis E. MHC-guided processing: binding of large antigen fragments. Nat Rev Immunol. 2003;3(8):621–9.

pubmed: 12974477 doi: 10.1038/nri1149

Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7(8):766–72.

pubmed: 16056268 doi: 10.1038/ncb0805-766

Hanafusa T, Chiovato L, Doniach D, Pujol-Borrell R, Russell RCG, Bottazzo GF. Aberrant expression of HLA-DR antigen on thyrocytes in Graves’ disease: relevance for autoimmunity. Lancet. 1983;322(8359):1111–5.

doi: 10.1016/S0140-6736(83)90628-1

Bottazzo G, Hanafusa T, Pujol-Borrell R, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 1983;322(8359):1115–9.

doi: 10.1016/S0140-6736(83)90629-3

Ballardini G, Bianchi F, Doniach D, Mirakian R, Pisi E, Bottazzo G. Aberrant expression of HLA-DR antigens on BILEDUCT epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet. 1984;324(8410):1009–13.

doi: 10.1016/S0140-6736(84)91108-5

Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med. 1986;164(4):1013–28.

pubmed: 2428913 doi: 10.1084/jem.164.4.1013

Dörner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004;16(3):246–53.

pubmed: 15103252 doi: 10.1097/00002281-200405000-00013

Song YW, Kang EH. The pathogenic role of rheumatoid factor in rheumatoid arthritis. Int J Clin Rheumatol. 2010;5(6):651–8.

doi: 10.2217/ijr.10.62

Zhang S, Tsuji H, Jin H, Kitagori K, Akizuki S, Nakashima R, et al. Rheumatoid factor recognizes specific domains of the IgG heavy chain complexed with HLA class II molecules. Rheumatology. 2023;62:3151.

pubmed: 36645239 doi: 10.1093/rheumatology/kead024

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

pubmed: 16420554 doi: 10.1111/j.1538-7836.2006.01753.x

McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci. 1990;87(11):4120–4.

pubmed: 2349221 pmcid: 54059 doi: 10.1073/pnas.87.11.4120

Galli M, Barbui T, Zwaal RF, Comfurius P, Bevers EM. Antiphospholipid antibodies: involvement of protein cofactors. Haematologica. 1993;78(1):1–4.

pubmed: 8491417

Ağar Ç, van Os GMA, Mörgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. β2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336–43.

pubmed: 20462962 doi: 10.1182/blood-2009-12-260976

Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994;179(2):457–62.

pubmed: 7507506 doi: 10.1084/jem.179.2.457

Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, et al. Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18(22):6228–39.

pubmed: 10562535 pmcid: 1171686 doi: 10.1093/emboj/18.22.6228

Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43(9):1982–93.

pubmed: 11014348 doi: 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2

Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504–12.

pubmed: 21953404 doi: 10.1002/art.33340

Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus. 2013;22(1):18–25.

pubmed: 22988029 pmcid: 4108293 doi: 10.1177/0961203312460722

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.

pubmed: 23045170 doi: 10.1002/art.37715

Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–30.

pubmed: 10088763 doi: 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6

Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318(25):1651–7.

pubmed: 2453802 doi: 10.1056/NEJM198806233182504

Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci. 1990;87(11):4115–9.

pubmed: 2161532 pmcid: 54058 doi: 10.1073/pnas.87.11.4115

Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide. Am J Pathol. 2005;167(1):47–58.

pubmed: 15972951 pmcid: 1603449 doi: 10.1016/S0002-9440(10)62952-5

Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol. 1997;8(3):386–94.

pubmed: 9071707 doi: 10.1681/ASN.V83386

Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.

pubmed: 19448636 pmcid: 2760083 doi: 10.1038/nm.1959

Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA–associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25(5):990–7.

pubmed: 24385592 pmcid: 4005303 doi: 10.1681/ASN.2013060606

Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992;41(2):375–83.

pubmed: 1313124 doi: 10.1038/ki.1992.52

Lu X, Garfield A, Rainger GE, Savage COS, Nash GB. Mediation of endothelial cell damage by serine proteases, but not superoxide, released from antineutrophil cytoplasmic antibody–stimulated neutrophils. Arthritis Rheum. 2006;54(5):1619–28.

pubmed: 16646023 doi: 10.1002/art.21773

Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Investig. 2002;110(7):955–63.

pubmed: 12370273 pmcid: 151154 doi: 10.1172/JCI0215918

Kallenberg CGM, Stegeman CA, Abdulahad WH, Heeringa P. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. Am J Kidney Dis. 2013;62(6):1176–87.

pubmed: 23810690 doi: 10.1053/j.ajkd.2013.05.009

Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463–73.

pubmed: 25003769 doi: 10.1038/nrrheum.2014.103

Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3(4):286–95.

pubmed: 25591468 doi: 10.1016/S2213-8587(14)70225-6

Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–65.

pubmed: 27797318 doi: 10.1056/NEJMra1510030

Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38.

pubmed: 20181974 pmcid: 3902010 doi: 10.1056/NEJMra0905750

McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290–302.

pubmed: 29674612 doi: 10.1038/nrrheum.2018.56

Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269–78.

pubmed: 29651121 doi: 10.1038/nrrheum.2018.41

Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636–44.

pubmed: 27533321 doi: 10.1097/BOR.0000000000000329

Ben-Chetrit E, Chan EK, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med. 1988;167(5):1560–71.

pubmed: 3367095 doi: 10.1084/jem.167.5.1560

Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev. 2009;8(7):632–7.

pubmed: 19393201 doi: 10.1016/j.autrev.2009.02.010

Menéndez A, Gómez J, Escanlar E, Caminal-Montero L, Mozo L. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity. 2013;46(1):32–9.

pubmed: 23039326 doi: 10.3109/08916934.2012.732131

Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018;16(1):5.

pubmed: 29540998 pmcid: 5840827 doi: 10.1186/s12948-018-0084-9

Eloranta M-L, Barbasso Helmers S, Ulfgren A-K, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti–Jo-1 or anti–Ro 52/anti–Ro 60 autoantibodies. Arthritis Rheum. 2007;56(9):3112–24.

pubmed: 17763410 doi: 10.1002/art.22860

Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601–7.

pubmed: 15692974 doi: 10.1002/art.20849

Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107–11.

pubmed: 17763414 doi: 10.1002/art.22856

Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, Sáez Moreno JA, Ortego CN. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27(6):1009–16.

pubmed: 20149324

Mahler EAM, Blom M, Voermans NC, van Engelen BGM, van Riel PLCM, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50(12):2206–13.

pubmed: 21571768 doi: 10.1093/rheumatology/ker088

Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun. 2012;39(1–2):77–82.

pubmed: 22402340 doi: 10.1016/j.jaut.2012.01.014

Dickson C, Fletcher AJ, Vaysburd M, Yang J-C, Mallery DL, Zeng J, et al. Intracellular antibody signalling is regulated by phosphorylation of the fc receptor TRIM21. elife. 2018;7:7.

doi: 10.7554/eLife.32660

Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O’Connell K, et al. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proc Natl Acad Sci. 2018;115(41):10440–5.

pubmed: 30209217 pmcid: 6187179 doi: 10.1073/pnas.1806314115

Rhodes DA, Isenberg DA. TRIM21 and the function of antibodies inside cells. Trends Immunol. 2017;38(12):916–26.

pubmed: 28807517 doi: 10.1016/j.it.2017.07.005

MacDonald KPA, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13–21.

pubmed: 27821504 pmcid: 5216261 doi: 10.1182/blood-2016-06-686618

Rozmus J. Monogenic immune diseases provide insights into the mechanisms and treatment of chronic graft-versus-host disease. Front Immunol. 2021;11:574569.

pubmed: 33613511 pmcid: 7889949 doi: 10.3389/fimmu.2020.574569

Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem H-P, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.

pubmed: 21263156 pmcid: 3062319 doi: 10.1182/blood-2010-08-302109

Kanda J, Nakasone H, Atsuta Y, Toubai T, Yokoyama H, Fukuda T, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transplant. 2014;49(2):228–35.

pubmed: 24076549 doi: 10.1038/bmt.2013.151

Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973–8.

pubmed: 15613541 doi: 10.1182/blood-2004-09-3660

Nakasone H, Tian L, Sahaf B, Kawase T, Schoenrock K, Perloff S, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood. 2015;125(20):3193–201.

pubmed: 25766725 pmcid: 4432013 doi: 10.1182/blood-2014-11-613323

Paul J, Nakasone H, Sahaf B, Wu F, Wang K, Ho V, et al. A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica. 2019;104(7):e314–e7.

pubmed: 30655371 pmcid: 6601098 doi: 10.3324/haematol.2018.199646

Rekvig OP. The anti-DNA antibody: origin and impact, dogmas and controversies. Nat Rev Rheumatol. 2015;11(9):530–40.

pubmed: 26034836 doi: 10.1038/nrrheum.2015.69

Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii T, Horita T, et al. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes. Rheumatology. 2013;52(7):1172–82.

pubmed: 23407388 doi: 10.1093/rheumatology/kes427

Filaci G, Grasso I, Vignola S, Imro MA, Scudeletti M, Puppo F, et al. DsDNA-specific T-cell lines in systemic lupus erythematosus patients: data suggesting their oligoclonality. Ann N Y Acad Sci. 1995;756:428–31.

pubmed: 7645865 doi: 10.1111/j.1749-6632.1995.tb44553.x

Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.

pubmed: 9278044 doi: 10.1038/42166

Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, et al. α-Synuclein in Parkinson’s disease: causal or bystander? J Neural Transm. 2019;126(7):815–40.

pubmed: 31240402 doi: 10.1007/s00702-019-02025-9

Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.

pubmed: 12498954 doi: 10.1016/S0197-4580(02)00065-9

Karpowicz RJ, Trojanowski JQ, Lee VMY. Transmission of α-synuclein seeds in neurodegenerative disease: recent developments. Lab Investig. 2019;99(7):971–81.

pubmed: 30760864 doi: 10.1038/s41374-019-0195-z

Araki K, Yagi N, Aoyama K, Choong C-J, Hayakawa H, Fujimura H, et al. Parkinson’s disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein. Proc Natl Acad Sci. 2019;116(36):17963–9.

pubmed: 31427526 pmcid: 6731630 doi: 10.1073/pnas.1906124116

Ozono T, Kimura Y, Suenaga T, Beck G, Jinno J, Aguirre C, et al. Extracellular transportation of α-synuclein by HLA class II molecules. Biochem Biophys Res Commun. 2023;644:25–33.

pubmed: 36621149 doi: 10.1016/j.bbrc.2022.12.082

Shimojo N, Kohno Y, Yamaguchi K, Kikuoka S, Hoshioka A, Niimi H, et al. Induction of graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci. 1996;93(20):11074–9.

pubmed: 8855311 pmcid: 38286 doi: 10.1073/pnas.93.20.11074

Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, et al. A novel murine model of graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol. 2002;168(6):2789–94.

pubmed: 11884447 doi: 10.4049/jimmunol.168.6.2789

Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in graves disease is the culprit as well as the victim. J Clin Investig. 2003;111(12):1897–904.

pubmed: 12813025 pmcid: 161420 doi: 10.1172/JCI200317069

Kaneda T, Honda A, Hakozaki A, Fuse T, Muto A, Yoshida T. An improved graves’ disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology. 2007;148(5):2335–44.

pubmed: 17255207 doi: 10.1210/en.2006-1077

Holthoff H-P, Goebel S, Li Z, Faßbender J, Reimann A, Zeibig S, et al. Prolonged TSH receptor a subunit immunization of female mice leads to a long-term model of Graves’ disease, tachycardia, and cardiac hypertrophy. Endocrinology. 2015;156(4):1577–89.

pubmed: 25562617 doi: 10.1210/en.2014-1813

Nakahara M, Mitsutake N, Sakamoto H, Chen C-R, Rapoport B, McLachlan SM, et al. Enhanced response to mouse thyroid-stimulating hormone (TSH) receptor immunization in TSH receptor-knockout mice. Endocrinology. 2010;151(8):4047–54.

pubmed: 20555026 doi: 10.1210/en.2010-0315

Carballido JM, Santamaria P. Taming autoimmunity: translating antigen-specific approaches to induce immune tolerance. J Exp Med. 2019;216(2):247–50.

pubmed: 30651299 pmcid: 6363422 doi: 10.1084/jem.20182287

Chazenbalk GD, Pichurin P, Chen C-R, Latrofa F, Johnstone AP, McLachlan SM, et al. Thyroid-stimulating autoantibodies in graves disease preferentially recognize the free a subunit, not the thyrotropin holoreceptor. J Clin Investig. 2002;110(2):209–17.

pubmed: 12122113 pmcid: 151066 doi: 10.1172/JCI0215745

Misrahi M, Milgrom E. Cleavage and shedding of the TSH receptor. Eur J Endocrinol. 1997;137:599–602.

pubmed: 9437220 doi: 10.1530/eje.0.1370599

Mach B, Steimle V, Martinez-Soria E, Reith W. REGULATION OF MHC CLASS II GENES: lessons from a disease. Annu Rev Immunol. 1996;14(1):301–31.

pubmed: 8717517 doi: 10.1146/annurev.immunol.14.1.301